Correlation between hsCRP and Anti-beta2GPI Antibody in Metabolic Syndrome

Meiriza Djohari, Mansyur Arif, Burhanuddin Bahar

Abstract


BACKGROUND: Several researches reported that inflammatory and immunological mechanism such as autoantibody to β2-glycoprotein I (anti β2GPI) appear as related factors in initiation and progress of atherosclerosis lesion in patient with autoimmune disease. Antibody to β2GPI titers are correlated with atherosclerosis and in vitro studies showed that they enhance oxidized low density lipoprotein (ox-LDL) uptake by macrophages. Immunization with auto-antigen β2GPI elicits an immune response to influence lesion progression that mostly happens in autoimmune subjects. The metabolic syndrome (MetS) is combination of several metabolic disorders such as obesity, dyslipidemia, Diabetes Mellitus (DM) and conditions due to inflammation and stress oxidative. The Correlation between inflammatory markers such as High sensitivity C-Reactive Protein (hsCRP) and anti-β2GPI antibody in MetS needs to be further investigated.

METHODS: This was an observational study with cross sectional design on subject with MetS as determined by the International Diabetes Federation (IDF) 2005’s criteria.

RESULTS:There was a positive and significant correlation between hsCRP and anti-β2GPI antibody in MetS group (r=0.406; p≤0.05) as compared to non-MetS group. We found that there was elevated level of anti-β2GPI antibody in hsCRP of 3-10 mg/L.

CONCLUSIONS: Anti-β2GPI antibody may be elevated in subjects with MetS who have low grade of inflammation as shown by hsCRP.

KEYWORDS: metabolic syndrome, inflammation, autoantigen, atherosclerosis, obesity


Full Text:

PDF

References


Reily MP, Rader JR. The metabolic syndrome: more than the sum of its parts? Circulation. 2003; 108: 1546-51, CrossRef.

Sumantri S, Pradono J. Gambaran kecenderungan penyakit tidak menular di Indonesia. Proceeding kajian masalah gizi, aktivitas fisik dan kesehatan. Bogor: [n.p]; 2005.

Cuillard C, Ruel G, Archer WR, Pomerleau S, Bergeron J, Couture P et al. Circulating levels of oxidative stress markers and endothelial adhesion molecules in men with abdominal obesity. J Clin Endocrinol Metab. 2005; 90: 6454-9, CrossRef.

Ridker PM, Rifai N, Rose L, Buring JE, Cook NC. Comparison of protein and low density lipopretin cholesterol in the predicition of first cardiovascular event. N Engl J Med. 2002; 47: 1557-65, CrossRef.

Verma S, Anderson TJ. Fundamentals of endotel function for the clinical cardiologist. Circulation. 2002; 105: 546-9, CrossRef.

Szimitko PE, Wang CH, Weisel RD, Almeida JR, Anderson TJ, Verma S. New markers of inflammation and endotel cell activation: part I. Circulation. 2003; 108: 1917-23, CrossRef.

Tabas I, Tall A, Accili D. The impact of macrophage insulin resistance on advensed atherosclerotic plaque progession. Circ Res. 2010; 106: 58-67, CrossRef.

George J, Harats D, Gilburd B, Afek A, Levy Y, Schneiderman Y, et al. Immunolocalization of ß2-glyciprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression. Circulation. 1999; 99: 2227-30, CrossRef.

Shoenfeld Y, Sherer Y, Harats D. Atherosclerosis as an infectious, infammatory and autoimmune disease. Trends in immunology. 2001; 22: 293-5, CrossRef.

Palinski W, Miller E, Witzum JL. Immunization of low density lipoprotein (LDL) receptor deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci USA. 1995; 92: 821-5, CrossRef.

Benjamin IJ, McMillan DR. Stress (heat shock) proteins: molecular chaperones in cardiovascular. Circ Res. 1998; 83: 117-32, CrossRef.

Wick G, Schett G, Amberger A, Kleindienst R, Xu Q. Is atherosclerosis an immunologically mediated disease? Immunol Today. 1995; 16: 27-33, CrossRef.

Shoenfield Y, Harats D, George J. Heat shock protein 60/65, beta2-glycoprotein I and oxidized LDL as players in murine atherosclerosis. J autoimmun. 2000; 15:199-202, CrossRef.

Labarrere CA, Zaloga GP. C-reactive protein: from innocent bystander to pivotal mediator of atherosclerosis. Am J Med. 2004; 117: 499-507, CrossRef.

Yeh ET, Palusinski. C-reactive protein: the pawn has been promoted to queen. Curr Atheroscler. 2003; 5: 101-5, CrossRef.

Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professional from the Center for Disease Control and Prevention and The American Heart Association. Circulation. 2003; 107: 499-511, CrossRef.

Libby P, Ridger PM. Iflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med. 2004; 116 (Suppl 1): 9-16, CrossRef.




DOI: https://doi.org/10.18585/inabj.v3i2.142

Indexed by:

                 

                  

               

     

 

The Prodia Education and Research Institute